{
  "dot_image": [
    "Red.png"
  ],
  "References": [
    
  ],
  "Article": [
    {
      "header": "Amikacin",
      "paragraph_US": [
        "Useful in monitoring adequacy of serum  concentration during amikacin therapy"
      ],
      "paragraph_SI": [
        "Useful in monitoring adequacy of serum  concentration during amikacin therapy"
      ]
    },
    {
      "header": "Reference Range",
      "paragraph_US": [
        "Therapeutic concentration (peak): 20.0-35.0  µg/mL"
      ],
      "paragraph_SI": [
        "Therapeutic concentration (peak): 34-52  µmol/L"
      ]
    },
    {
      "header": "Interpretation",
      "paragraph_US": [
        "Therapeutic concentration (trough): <8.0 µg/mL"
      ],
      "paragraph_SI": [
        "Therapeutic concentration (trough): <14.0 µmol/L"
      ]
    },
    {
      "header": "Clinical  Information",
      "paragraph_US": [
        "For conventional (non-pulse) dosing  protocols, clinical effects may not be achieved if the peak serum concentration  is <20.0 µg/mL. Toxicity may occur if the peak serum concentration is  maintained >35.0 µg/mL for a prolonged period of time. Trough concentrations should fall to <8.0 µg/mL. Toxicity may  occur if the trough serum concentration is maintained >10.0 µg/mL for prolonged  periods of time."
      ],
      "paragraph_SI": [
        "For conventional (non-pulse) dosing  protocols, clinical effects may not be achieved if the peak serum concentration  is <34.0 µmol/L. Toxicity may occur if the peak serum concentration is  maintained >52.0 µmol/L for a prolonged period of time. Trough concentrations should fall to <14.0 µmol/L. Toxicity may  occur if the trough serum concentration is maintained >17.0 µmol/L for prolonged  periods of time."
      ]
    }
  ]
}